Tilray Brands, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
Tilray Brands, Inc. (TLRY) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $3.80 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-07-28
- Tilray Brands, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2026 was $3.80M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|
| 2026-05-31 | $3.80M 10-K · filed 2026-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |